Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
81 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mylan Investigator Site
Red Deer, Alberta, Canada
- Mylan Investigator Site.
Vancouver, British Columbia, Canada
- Mylan Investigator Site
Winnipeg, Manitoba, Canada
- Mylan Investigator Site
Laval, Quebec, Canada
- Mylan Investigator Site
Montreal, Quebec, Canada
- Mylan Investigator Site
Brno-Bohunice, Czechia
- Mylan Investigator Site
Olomouc, Czechia
- Mylan Investigator Site
Pardubice, Czechia
- Mylan Investigator Site
Prague, Czechia
- Mylan Investigator Site
Prague, Czechia
- Mylan Investigator Site
České Budějovice, Czechia
- Mylan Investigator Site
Pärnu, Estonia
- Mylan Investigator Site
Tallinn, Estonia
- Mylan Investigator Site
Tartu, Estonia
- Mylan Investigator Site
Aschaffenburg, Bavaria, Germany
- Mylan Investigator Site
Münster, North Rhine-Westphalia, Germany
- Mylan Investigator Site
Hohenmölsen, Saxony-Anhalt, Germany
- Mylan Investigator Site
Hamburg, Germany
- Mylan Investigator Site
Hamburg, Germany
- Mylan Investigator Site
Budapest, Hungary
- Mylan Investigator Site
Budapest, Hungary
- Mylan Investigator Site
Eger, Hungary
- Mylan Investigator Site
Létavértes, Hungary
- Mylan Investigator Site
Miskolc, Hungary
- Mylan Investigator Site
Szeged, Hungary
- Mylan Investigator Site
Limbaži, Latvia
- Mylan Investigator Site
Ogre, Latvia
- Mylan Investigator Site
Riga, Latvia
- Mylan Investigator Site
Riga, Latvia
- Mylan Investigator Site
Sigulda, Latvia
- Mylan Investigator Site
Talsi, Latvia
- Mylan Investigator Site
Bratislava, Slovakia
- Mylan Investigator Site
Bratislava, Slovakia
- Mylan Investigator Site
Dolný Kubín, Slovakia
- Mylan Investigator Site
Levice, Slovakia
- Mylan Investigator Site
Nové Zámky, Slovakia
- Mylan Investigator Site
Prievidza, Slovakia
- Mylan Investigator Site
Rimavská Sobota, Slovakia
- Mylan Investigator Site
Trebišov, Slovakia
- Mylan Investigator Site
Ľubochňa, Slovakia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2015
- Primary completion
- 31 Mar 2017
- Completion
- 31 Jul 2017
- Last update posted
- 3 Mar 2022
- Registered enrollment
- 127
- Registry id
- NCT02666430
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.